The Company was founded by Samih Darwazah in 1978 in Amman in Jordan.  In August 1996 it became the first Arab company to export pharmaceutical products to the United States.  It was first listed on the London Stock Exchange in 2005.  Recent acquisitions include Instituto Biochimico Pavese Pharma in Italy in 2005  and Jazeera Pharmaceutical Industries in Saudi Arabia in 2006.  In 2007 the Company went on to buy APM in Jordan ,  Alkan Pharma in Egypt , APM and Al Jazeera Pharma in Saudi Arabia  Thymoorgan in Germany  and Ribosepharm in Germany.  It also acquired Multi-Source Injectables in the USA in October 2010.  In May 2011 Hikma Pharmaceuticals PLC complete the acquisition of Baxter Healthcare Corporation's US generic injectables business (Multi-Source Injectables or MSI). 
These two organisations were merged by the Government in 1981 to form a new, non-statutory body called the British Technology Group .  It acted principally to license and commercialise the use of publicly funded developments. The Group was put onto a statutory footing in the British Technology Group Act 1991  with HM Treasury initially being the only shareholder. Subsequently, in March 1992, Cinven arranged a management buy-out from the Government. The company later floated on the London Stock Exchange in 1995.  Three years later, on 27 May 1998, the Group adopted its present name. It now focuses its work on developing and commercialising medical innovations.